398 filings
8-K
EVFM
Evofem Biosciences, Inc.
15 May 24
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
6:50am
10-Q
2024 Q1
EVFM
Evofem Biosciences, Inc.
Quarterly report
15 May 24
6:45am
8-K
EVFM
Evofem Biosciences, Inc.
2 May 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EVFM
Evofem Biosciences, Inc.
28 Mar 24
Regulation FD Disclosure
5:11pm
10-K
2023 FY
EVFM
Evofem Biosciences, Inc.
Annual report
27 Mar 24
8:40am
8-K
6rvlgi27o
27 Mar 24
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
8:36am
8-K
zss3 mjmp2pg31p
6 Mar 24
Entry into a Material Definitive Agreement
5:14pm
8-K
8zvawudu8m ohg
1 Feb 24
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
9:05am
8-K
bbt9t4qy
31 Jan 24
Entry into a Material Definitive Agreement
4:26pm
8-K/A
h9kbz 4oof0
25 Jan 24
Financial Statements and Exhibits
4:23pm
8-K
qguzc r4riilufv9dhgn
11 Jan 24
Entry into a Material Definitive Agreement
4:53pm
8-K
t0pubb1xs5t0l7uv5
26 Dec 23
Entry into a Material Definitive Agreement
5:37pm
8-K
z43nk6x
12 Dec 23
Entry into a Material Definitive Agreement
5:17pm
8-K
uadp3nn791xey
7 Dec 23
Entry into a Material Definitive Agreement
4:05pm
8-K
e01kk1tkzzpt67ve24w
14 Nov 23
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
12:00am
8-K
ifkfkrcbybzzn
24 Oct 23
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
7:40am
D
5p4 5uzguzj7q
10 Oct 23
$2.88 mm in debt / options / securities to be acquired, sold $2.88 mm, 14 investors
7:57pm
8-K
h6oio0q0 sk564j7b
3 Oct 23
Entry into a Material Definitive Agreement
4:07pm
8-K
gwxc2a dsf0hjq1
27 Sep 23
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem’s Phexxi Patents Expire
8:50am